Overcoming Challenges in Viral Vector Manufacturing to Meet Commercial Demand for Gene Therapies, Upcoming Webinar Hosted by Xtalks

Gene therapy is reshaping modern medicine, offering the potential for lasting, even curative treatments for a wide range of ...
Seeking Alpha

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. "uniQure has been a pioneer in gene ...
Medical Xpress

Study offers real-world data on commercial implementation of gene therapies for sickle cell disease, beta thalassemia

A study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers lessons learned to inform best practices as manufacturers and medical centers ...
Business Wire

bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “bluebird”) today announced the details of its U.S. commercial infrastructure to support timely, equitable ...
The Conversation

When there’s no commercial incentive to develop gene therapy – hospitals will try to fill the gap

Individually, rare diseases are rare, but there are so many rare diseases that over 400 million people are affected worldwide. Together, rare diseases aren’t so rare. Only 5% of rare diseases have an ...
Nasdaq

bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Price of LYFGENIA reflects its value as a potentially curative gene therapy for sickle cell disease through durable production of anti-sickling adult hemoglobin (HbAT87Q) and resolution of ...